Why Have Wockhardt Shares Rallied 37% in the Last Two Trading Sessions?

Synopsis: Wockhardt Ltd shares rally 37%  in the last two days after FDA approval of ZAYNICH™ for cUTI, which showed 89% cure vs 68.4% with meropenem in Phase 3 ENHANCE-1, with QIDP/Fast Track status and global filings underway.

The shares of a Mid-Cap company specialising in drug discovery, the development of advanced antibiotics, biopharmaceuticals, and complex generic formulations, are in focus in today’s trade as they have rallied 37 percent in the last two trading sessions, here’s why.

With a market capitalization of Rs. 36,312.27 crores in the day’s trade, the shares of Wockhardt Ltd rose by 19.1 percent, reaching a high of Rs. 2,420.00 per share compared to its previous closing price of Rs. 2,030.70 per share.

What Happened 

Wockhardt Ltd shares rally 37 percent in the last two days upon announcing that it has received U.S. Food and Drug Administration (FDA) approval for ZAYNICH™ (cefepime and zidebactam), a novel intravenous antibiotic indicated for the treatment of adult patients with complicated urinary tract infections (cUTI), including pyelonephritis caused by susceptible Gram-negative pathogens. The drug has also received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA.

ZAYNICH™ is a combination of the fourth-generation cephalosporin cefepime and zidebactam, designed to act synergistically by targeting multiple penicillin-binding proteins. This multi-target mechanism provides strong bactericidal activity against difficult-to-treat, multidrug-resistant Gram-negative bacteria, addressing a major and growing global healthcare challenge.

The FDA approval was supported by results from the Phase 3 ENHANCE-1 clinical trial, a randomised, double-blind, multicenter study involving 530 patients across multiple countries. The trial showed that ZAYNICH™ achieved a composite clinical cure and microbiological response rate of 89.0%, compared to 68.4% with meropenem, demonstrating a treatment difference of 20.6%. The drug was also generally well tolerated.

Complicated urinary tract infections account for over 600,000 hospitalisations annually in the U.S., with rising cases driven by antimicrobial-resistant bacteria. The Drugs Controller General of India has also approved ZAYNICH™, and a Marketing Authorisation Application has been submitted to the European Medicines Agency, marking its progress toward global availability.

Dr Dennis Deruelle, MD, FHM, Chief Medical Officer at Wockhardt, said that the threat of drug-resistant infections is an escalating crisis that leaves clinicians with fewer treatment options for patients facing aggressive pathogens. He added that the FDA approval of ZAYNICH™ marks a significant step forward in validating a new therapeutic option for these underserved patient groups. He further noted that this milestone reflects Wockhardt’s commitment to addressing critical unmet medical needs and brings renewed hope to the families the company serves.

Dr Habil F. Khorakiwala, Founder and Chairman of Wockhardt Group, said that the approval is a significant realisation of the company’s mission to provide patients with novel antibiotics addressing the urgent global health threat of antimicrobial resistance. He further noted that ZAYNICH™ is the first New Chemical Entity fully developed and commercialised by an Indian pharmaceutical company to receive FDA approval, marking a historic milestone for both Wockhardt and the Indian pharmaceutical industry.

Financials & Others

The company’s revenue rose by 29.88 percent from Rs. 743 crores in March 2025 to Rs. 965 crores in March 2026. Meanwhile, the net loss of Rs. 45 crores turned into a profit of Rs. 164 crores during the same period.

The company reported a Return on Capital Employed (ROCE) of 7.55% and a Return on Equity (ROE) of 6.11%, indicating moderate efficiency in generating returns from its capital and shareholders’ equity. The debt-to-equity ratio stood at 0.45, reflecting a relatively balanced capital structure with moderate reliance on debt financing.

Wockhardt is a global pharmaceutical and biotechnology company focused on developing innovative anti-infective solutions. With a strong legacy of scientific excellence and a mission to combat antimicrobial resistance, the company is developing next-generation therapies for global healthcare needs. 

Its pipeline includes six antibiotics at various stages of clinical development and commercialisation, targeting both Gram-negative and Gram-positive infections, all of which have received Qualified Infectious Disease Product (QIDP) designation from the US FDA.

The company employs around 3,200 people representing 27 nationalities and operates across India, the UK, the U.S., Ireland, Switzerland, France, Mexico, Russia, and other countries. It has manufacturing and research facilities in India and the UK, along with a manufacturing site in Ireland. Wockhardt maintains a strong international presence, with about 78% of its global revenues coming from international markets, including significant contributions from Europe and India.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Why Have Wockhardt Shares Rallied 37% in the Last Two Trading Sessions? appeared first on Trade Brains.